<?xml version="1.0" encoding="UTF-8"?>
<p>In terms of its antiviral mechanism of action, after being metabolized to its triphosphate form, ribavirin competes with the physiological nucleoside (adenosine/guanosine) for the RdRp active site [
 <xref rid="B124-jcm-09-02084" ref-type="bibr">124</xref>] and is incorporated in the RNA strand, but in some experimental conditions, does not terminate RNA chain elongation, but rather acts as a viral mutagenesis inducing agent [
 <xref rid="B125-jcm-09-02084" ref-type="bibr">125</xref>]. The drug is currently used in the treatment of hepatitis C virus (HCV) infection [
 <xref rid="B124-jcm-09-02084" ref-type="bibr">124</xref>].
</p>
